Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
February 19, 2026
Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders,